drugset
Drugs / RTS,S/AS01E
last change Aug 2022 re-read 9 days ago

RTS,S/AS01E

Vaccine

Developed for
Plasmodium falciparum malaria
Investigated by
DF/Net · FHI Clinical SA Proprietary Limited · GlaxoSmithKline · Kenya Medical Research Institute · PATH · Walter Reed Army Institute of Research (WRAIR)

Trials 1

today NCT04661579 · Ph 2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04661579 Nov 2020 → Jun 2022 Plasmodium falciparum malaria PATH Completed Met primary

Press releases naming this drug 2 releases

DateIssuerRelease
2021-10-06 GlaxoSmithKline GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine gsk.com ↗
2021-01-27 GlaxoSmithKline GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine gsk.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RTS,S/AS01E ClinicalTrials.gov intervention name — accepted as the source's own label NCT04661579 ↗
Modality Vaccine “GSK has developed a candidate vaccine against malaria caused by P. falciparum called RTS,S/AS01E.” NCT04661579 ↗
Route Intramuscular “Participants received 3 vaccinations with malarial vaccine RTS,S/AS01E by intramuscular injection” NCT04661579 ↗